Clinical Trial Update: Study of Pamidronate for the Prevention of Heterotopic Ossification [NA]

View source ↗

Summary

The clinical trial studying pamidronate for prevention of heterotopic ossification has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heterotopic Ossification

Drugs mentioned

• Pamidronate (pamidronate disodium)

Snippet

Sponsor: University Hospital, Basel, Switzerland | Conditions: Heterotopic Ossification | NA | Status: WITHDRAWN